Topical Dorzolamide-Timolol With Intravitreous Anti–Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration

Topical dorzolamide hydrochloride-timolol appears to reduce central subfield thickness and subretinal fluid in eyes of patients with neovascular age-related macular degeneration (AMD) and incomplete response to anti-vascular endothelial growth factor (VEGF) therapy, according to a study published online Feb. 25 in JAMA Ophthalmology. Jayanth Sridhar, M.D., from the Thomas Jefferson University in Philadelphia, and colleagues…

Retinitis Pigmentosa: FDA approves first retinal implant for advanced adult RP

Retinitis pigmentosa (RP) is a group of inherited disorders characterized by progressive peripheral vision loss and night vision difficulties (nyctalopia) that can lead to central vision loss. The US Food and Drug Administration (FDA) has approved the first retinal implant, the Argus II Retinal Prosthesis System, for adults aged 25 years or older with advanced RP. The…